Characterization of the core patient cohort at diagnosis
| Characteristic . | No. of patients . | % . |
|---|---|---|
| No. of patients | 155 | 100 |
| Age, years | ||
| Median | 51 | |
| Range | 20-79 | |
| Sex | ||
| Female | 92 | 60 |
| Male | 62 | 40 |
| AML history | ||
| De novo | 148 | 95 |
| Secondary | 5 | 3 |
| Therapy-related | 1 | 1 |
| Not available | 1 | 1 |
| Cytogenetics | ||
| Normal karyotype | 109 | 70 |
| Aberrant karyotype | 23 | 15 |
| Not available | 23 | 15 |
| FLT3-ITD status | ||
| Wild-type | 95 | 61 |
| ITD-mutated | 60 | 39 |
| BM blasts | ||
| Median | 67 | |
| Range | 5-97.5 | |
| WBC count, Gpt/L | ||
| Median | 33 | |
| Range | 0.9-290 | |
| Serum LDH, U/L | ||
| Median | 472 | |
| Range | 144-4088 | |
| Response | ||
| Patients achieving CR | 155 | |
| Patients with relapse | 47 | |
| Transplantation as post-remission therapy | ||
| Autologous | 17 | |
| Related SCT | 19 | |
| Unrelated SCT | 21 | |
| Follow-up after chemotherapy, days | ||
| Median | 535 | |
| Range | 388-682 | |
| Follow-up after SCT calculated from day 0 of transplant, days | ||
| Median | 1258 | |
| Range | 1001-1515 | |
| Characteristic . | No. of patients . | % . |
|---|---|---|
| No. of patients | 155 | 100 |
| Age, years | ||
| Median | 51 | |
| Range | 20-79 | |
| Sex | ||
| Female | 92 | 60 |
| Male | 62 | 40 |
| AML history | ||
| De novo | 148 | 95 |
| Secondary | 5 | 3 |
| Therapy-related | 1 | 1 |
| Not available | 1 | 1 |
| Cytogenetics | ||
| Normal karyotype | 109 | 70 |
| Aberrant karyotype | 23 | 15 |
| Not available | 23 | 15 |
| FLT3-ITD status | ||
| Wild-type | 95 | 61 |
| ITD-mutated | 60 | 39 |
| BM blasts | ||
| Median | 67 | |
| Range | 5-97.5 | |
| WBC count, Gpt/L | ||
| Median | 33 | |
| Range | 0.9-290 | |
| Serum LDH, U/L | ||
| Median | 472 | |
| Range | 144-4088 | |
| Response | ||
| Patients achieving CR | 155 | |
| Patients with relapse | 47 | |
| Transplantation as post-remission therapy | ||
| Autologous | 17 | |
| Related SCT | 19 | |
| Unrelated SCT | 21 | |
| Follow-up after chemotherapy, days | ||
| Median | 535 | |
| Range | 388-682 | |
| Follow-up after SCT calculated from day 0 of transplant, days | ||
| Median | 1258 | |
| Range | 1001-1515 | |
LDH, lactate dehydrogenase; WBC, white blood cell (count).